

## LRRK2 (Y1699C), Active

Recombinant human protein expressed in Sf9 cells

**Catalog # L10-12DG**

Lot # T812-1

### Product Description

Recombinant human LRRK2 (Y1699C) (968-end) was expressed by baculovirus in Sf9 insect cells using an N-terminal GST tag. The LRRK2 gene accession number is [NM\\_198578](#).

### Gene Aliases

PARK8; RIPK7; ROCO2; AURA17; DARDARIN

### Formulation

Recombinant protein stored in 50mM Tris-HCl, pH 7.5, 150mM NaCl, 10mM glutathione, 0.1mM EDTA, 0.25mM DTT, 0.1mM PMSF, 25% glycerol.

### Storage and Stability

Store product at -70°C. For optimal storage, aliquot target into smaller quantities after centrifugation and store at recommended temperature. For most favorable performance, avoid repeated handling and multiple freeze/thaw cycles.


### Scientific Background

LRRK2 or leucine-rich repeat kinase is a protein with an ankyrin repeat region, a leucine-rich repeat (LRR) domain, a kinase domain, a DFG-like motif, a RAS domain, a GTPase domain, a MLK-like domain, and a WD40 domain. Mutations in LRRK2 are the most frequent known cause of autosomal dominant and idiopathic Parkinson's disease with prevalent mutations being found within the GTPase and kinase domains (1). LRRK2 cooperates with MET to promote efficient tumor cell growth and survival in various cancers. Down-regulation of LRRK2 in cultured tumor cells compromises MET activation and selectively reduces downstream MET signaling to mTOR and STAT3 (2).

### References


1. Yao C, LRRK2-mediated neurodegeneration and dysfunction of dopaminergic neurons in a Caenorhabditis elegans model of Parkinson's disease. *Neurobiol Dis.* 2010 Oct;40(1):73-81.
2. Looyenga BD, Chromosomal amplification of leucine-rich repeat kinase-2 (LRRK2) is required for oncogenic MET signaling in papillary renal and thyroid carcinomas. *Proc Natl Acad Sci U S A.* 2011 Jan 25;108(4):1439-44.

### Specific Activity



The specific activity of LRRK2 (Y1699C) was determined to be **8 nmol/min/mg** as per activity assay protocol.

### Purity



The purity of LRRK2 (Y1699C) was determined to be **>70%** by densitometry, approx. MW **210 kDa**.

## LRRK2 (Y1699C), Active

Recombinant human protein expressed in Sf9 cells

Catalog #	L10-12DG
Specific Activity	8 nmol/min/mg
Lot #	T812-1
Purity	>70%
Concentration	0.05 µg/µl
Stability	1yr at -70°C from date of shipment
Storage & Shipping	Store product at -70°C. For optimal storage, aliquot target into smaller quantities after centrifugation and store at recommended temperature. For most favorable performance, avoid repeated handling and multiple freeze/thaw cycles. Product shipped on dry ice.

To place your order, please contact us by phone 1-(604)-232-4600, fax 1-604-232-4601 or by email: [orders@signalchem.com](mailto:orders@signalchem.com)  
[www.signalchem.com](http://www.signalchem.com)

**FOR IN VITRO RESEARCH PURPOSES ONLY. NOT INTENDED FOR USE IN HUMAN OR ANIMALS.**

# Activity Assay Protocol

## Reaction Components

### Active Kinase (Catalog #: L10-12DG)

Active LRRK2 (Y1699C) (0.1µg/µl) diluted with Kinase Dilution Buffer III (Catalog #: K23-09) and assayed as outlined in sample activity plot. (Note: these are suggested working dilutions and it is recommended that the researcher perform a serial dilution of Active LRRK2 (Y1699C) for optimal results).

### Kinase Dilution Buffer III (Catalog #: K23-09)

Kinase Assay Buffer I (Catalog #: K01-09) diluted at a 1:4 ratio (5X dilution) with 50ng/µl BSA solution.

### Kinase Assay Buffer I (Catalog #: K01-09)

Buffer components: 25mM MOPS, pH 7. 2, 12.5mM β-glycerol-phosphate, 25mM MgCl<sub>2</sub>, 5mM EGTA, 2mM EDTA. Add 0.25mM DTT to Kinase Assay Buffer prior to use.

### [<sup>33</sup>P]-ATP Assay Cocktail

Prepare 250µM [<sup>33</sup>P]-ATP Assay Cocktail in a designated radioactive working area by adding the following components: 150µl of 10mM ATP Stock Solution (Catalog #: A50-09), 100µl [<sup>33</sup>P]-ATP (1mCi/100µl), 5.75ml of Kinase Assay Buffer I (Catalog #: K01-09). Store 1ml aliquots at -20°C.

### 10mM ATP Stock Solution (Catalog #: A50-09)

Prepare ATP stock solution by dissolving 55mg of ATP in 10ml of Kinase Assay Buffer I (Catalog #: K01-09). Store 200µl aliquots at -20°C.

### Substrate (Catalog #: L10-58)

LRRKtide (RLGRDKYKTLRQIRQ) diluted in distilled H<sub>2</sub>O to a final concentration of 1mg/ml.

## Assay Protocol

- Step 1.** Thaw [<sup>33</sup>P]-ATP Assay Cocktail in shielded container in a designated radioactive working area.
- Step 2.** Thaw the Active LRRK2 (Y1699C), Kinase Assay Buffer, Substrate and Kinase Dilution Buffer on ice.
- Step 3.** In a pre-cooled microfuge tube, add the following reaction components bringing the initial reaction volume up to 20µl:
  - Component 1.** 10µl of diluted Active LRRK2 (Y1699C) (Catalog # L10-12DG)
  - Component 2.** 5µl of 1mg/ml stock solution of substrate (Catalog # L10-58)
  - Component 3.** 5µl distilled H<sub>2</sub>O (4°C)
- Step 4.** Set up the blank control as outlined in step 3, excluding the addition of the substrate. Replace the substrate with an equal volume of distilled H<sub>2</sub>O.
- Step 5.** Initiate the reaction by the addition of 5 µl [<sup>33</sup>P]-ATP Assay Cocktail bringing the final volume up to 25µl and incubate the mixture in a water bath at 30°C for 15 minutes.
- Step 6.** After the 15 minute incubation period, terminate the reaction by spotting 20 µl of the reaction mixture onto individual pre-cut strips of phosphocellulose P81 paper.
- Step 7.** Air dry the pre-cut P81 strip and sequentially wash in a 1% phosphoric acid solution (dilute 10ml of phosphoric acid and make a 1L solution with distilled H<sub>2</sub>O) with constant gentle stirring. It is recommended that the strips be washed a total of 3 intervals for approximately 10 minutes each.
- Step 8.** Count the radioactivity on the P81 paper in the presence of scintillation fluid in a scintillation counter.
- Step 9.** Determine the corrected cpm by removing the blank control value (see Step 4) for each sample and calculate the kinase specific activity as outlined below.

### Calculation of [<sup>33</sup>P]-ATP Specific Activity (SA) (cpm/pmol)

Specific activity (SA) = cpm for 5 µl [<sup>33</sup>P]-ATP / pmoles of ATP (in 5 µl of a 250 µM ATP stock solution, i.e., 1250 pmoles)

### Kinase Specific Activity (SA) (pmol/min/µg or nmol/min/mg)

Corrected cpm from reaction / [(SA of <sup>33</sup>P-ATP in cpm/pmol)\*(Reaction time in min)\*(Enzyme amount in µg or mg)]\*[(Reaction Volume) / (Spot Volume)]

To place your order, please contact us by phone 1-(604)-232-4600, fax 1-604-232-4601 or by email: [orders@signalchem.com](mailto:orders@signalchem.com)  
[www.signalchem.com](http://www.signalchem.com)

**FOR IN VITRO RESEARCH PURPOSES ONLY. NOT INTENDED FOR USE IN HUMAN OR ANIMALS.**